EGFR and neoplasm: Although tracers based on EGFR TKI that are in clinical use, when labeled inertly, provide the best PK behavior metrics to investigate tumor sensitivity to the respective TKI, the development of such tracers is inherently delayed, as clinical safety and efficacy data of the parent TKI need to be established.